TY - JOUR
T1 - Intracutaneous transplantation of islets within a biodegradable temporizing matrix as an alternative site for islet transplantation
AU - Rojas-Canales, Darling
AU - Walters, Stacey N.
AU - Penko, Daniella
AU - Cultrone, Daniele
AU - Bailey, Jacqueline
AU - Chtanova, Tatyana
AU - Nitschke, Jodie
AU - Johnston, Julie
AU - Kireta, Svjetlana
AU - Loudovaris, Thomas
AU - Kay, Thomasw
AU - Kuchel, Tim R.
AU - Hawthorne, Wayne
AU - O'connell, Philip J.
AU - Korbutt, Greg
AU - Greenwood, John E.
AU - Grey, Shane T.
AU - Drogemuller, Chris J.
AU - Coates, P. Toby
N1 - Publisher Copyright:
© 2023, American Diabetes Association Inc.. All rights reserved.
PY - 2023/6
Y1 - 2023/6
N2 - Intrahepatic islet transplantation for type 1 diabetes is limited by the need for multiple infusions and poor islet viability posttransplantation. The development of alternative transplantation sites is necessary to improve islet survival and facilitate monitoring and retrieval. We tested a clinically proven biodegradable temporizing matrix (BTM), a polyurethane-based scaffold, to generate a well-vascularized intracutaneous "neodermis" within the skin for islet transplantation. In murine models, BTM did not impair syngeneic islet renal-subcapsular transplant viability or function, and it facilitated diabetes cure for over 150 days. Furthermore, BTM supported functional neonatal porcine islet transplants into RAG-1_/_ mice for 400 days. Hence, BTM is non-toxic for islets. Two-photon intravital imaging used to map vessel growth through time identified dense vascular networks, with significant collagen deposition and increases in vessel mass up to 30 days after BTM implantation. In a pre-clinical porcine skin model, BTM implants created a highly vascularized intracutaneous site by day 7 postimplantation. When syngeneic neonatal porcine islets were transplanted intracutaneously, the islets remained differentiated as insulin-producing cells, maintained normal islet architecture, secreted c-peptide, and survived for over 100 days. Here, we show that BTMfacilitates formation of an islet-supportive intracutaneous neodermis in a porcine preclinicalmodel, as an alternative islet-transplant site.
AB - Intrahepatic islet transplantation for type 1 diabetes is limited by the need for multiple infusions and poor islet viability posttransplantation. The development of alternative transplantation sites is necessary to improve islet survival and facilitate monitoring and retrieval. We tested a clinically proven biodegradable temporizing matrix (BTM), a polyurethane-based scaffold, to generate a well-vascularized intracutaneous "neodermis" within the skin for islet transplantation. In murine models, BTM did not impair syngeneic islet renal-subcapsular transplant viability or function, and it facilitated diabetes cure for over 150 days. Furthermore, BTM supported functional neonatal porcine islet transplants into RAG-1_/_ mice for 400 days. Hence, BTM is non-toxic for islets. Two-photon intravital imaging used to map vessel growth through time identified dense vascular networks, with significant collagen deposition and increases in vessel mass up to 30 days after BTM implantation. In a pre-clinical porcine skin model, BTM implants created a highly vascularized intracutaneous site by day 7 postimplantation. When syngeneic neonatal porcine islets were transplanted intracutaneously, the islets remained differentiated as insulin-producing cells, maintained normal islet architecture, secreted c-peptide, and survived for over 100 days. Here, we show that BTMfacilitates formation of an islet-supportive intracutaneous neodermis in a porcine preclinicalmodel, as an alternative islet-transplant site.
UR - http://www.scopus.com/inward/record.url?scp=85159767624&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85159767624&partnerID=8YFLogxK
U2 - 10.2337/db21-0841
DO - 10.2337/db21-0841
M3 - Article
C2 - 36929171
AN - SCOPUS:85159767624
SN - 0012-1797
VL - 72
SP - 758
EP - 768
JO - Diabetes
JF - Diabetes
IS - 6
ER -